We are a voluntary non-profit making consortium of Pharmaceutical Companies.
The member companies develop new products for human use for Pulmonary or Nasal route of delivery intended to be used in the European Market.
Trudell Medical International
The vision for EPAG is that the group will remain the principal industry-based opinion leading and influencing group for the pharmaceutical development and regulation of products for pulmonary and nasal delivery in Europe.
EPAG will continue to be recognised internationally as a valued contributor to the world-wide pulmonary and nasal product development and regulation arena.
Tarlochan S. Purewal, Jolyon P. Mitchell, PhD and Hlack Mohammed, PhD have jointly written an article on behalf of the European Pharmaceutical Aerosol Group (EPAG) which was published in Inhalation, August 2023, Volume 17, Number 4 entitled “An Overview of the European Pharmaceutical Aerosol Group (EPAG)”. This is a brief history of the formation of EPAG, its constitution, objectives, structure, influence, publications and input to regulatory guidance documents.
The article can be found using the following link: